Unlocking Serology’s Secrets
We explore the work of researchers aiming to revolutionize the diagnosis of fibromyalgia and cholera using blood-based technologies…
Jonathan James | | Longer Read
Routine blood tests – though arguably overused at times – play a central role in serious disease screening (1). Dreams of breakthrough technology capable of cheaply diagnosing multiple diseases from a single drop of blood appear to have been dashed for now; Elizabeth Holmes, CEO of Silicon Valley startup Theranos, perpetuated breathtakingly false claims about the ability of her company’s tests – and the legal fallout continues (2). And though groups of researchers continue to push the limits of what’s possible in (accessible) multiple-disease diagnosis – the winners of the Qualcomm Tricorder XPRIZE being one example – in many scenarios, a simple blood test for a single disease represents a significant challenge.
And so, thousands of researchers continue to explore how blood-based testing modalities could meet unmet clinical need. Here, we focus on the work of two such groups of scientists. Although at different stages along the translational journey and divided by very different technologies, they are united in their desire to improve the diagnosis of diseases that evade detection.
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts